Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol

Yaakov Dickstein, Leonard Leibovici, Dafna Yahav, Noa Eliakim-Raz, George L Daikos, Anna Skiada, Anastasia Antoniadou, Yehuda Carmeli, Amir Nutman, Inbar Levi, Amos Adler, Emanuele Durante-Mangoni, Roberto Andini, Giusi Cavezza, Johan W Mouton, Rixt A Wijma, Ursula Theuretzbacher, Lena E Friberg, Anders N Kristoffersson, Oren Zusman, Fidi Koppel, Yael Dishon Benattar, Sergey Altunin, Mical Paul, AIDA consortium, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav, Noa Eliakim-Raz, George L Daikos, Anna Skiada, Anastasia Antoniadou, Yehuda Carmeli, Amir Nutman, Inbar Levi, Amos Adler, Emanuele Durante-Mangoni, Roberto Andini, Giusi Cavezza, Johan W Mouton, Rixt A Wijma, Ursula Theuretzbacher, Lena E Friberg, Anders N Kristoffersson, Oren Zusman, Fidi Koppel, Yael Dishon Benattar, Sergey Altunin, Mical Paul, AIDA consortium

Abstract

Introduction: The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective and more toxic than modern antibiotics. In vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomised controlled study is necessary for clarification.

Methods and analysis: This is a multicentre, investigator-initiated, open-label, randomised controlled superiority 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy for infections caused by carbapenem-resistant Gram-negative bacteria. The study is being conducted in 6 centres in 3 countries (Italy, Greece and Israel). We include patients with hospital-associated and ventilator-associated pneumonia, bloodstream infections and urosepsis. The primary outcome is treatment success at day 14, defined as survival, haemodynamic stability, stable or improved respiratory status for patients with pneumonia, microbiological cure for patients with bacteraemia and stability or improvement of the Sequential Organ Failure Assessment (SOFA) score. Secondary outcomes include 14-day and 28-day mortality as well as other clinical end points and safety outcomes. A sample size of 360 patients was calculated on the basis of an absolute improvement in clinical success of 15% with combination therapy. Outcomes will be assessed by intention to treat. Serum colistin samples are obtained from all patients to obtain population pharmacokinetic models. Microbiological sampling includes weekly surveillance samples with analysis of resistance mechanisms and synergy. An observational trial is evaluating patients who met eligibility requirements but were not randomised in order to assess generalisability of findings.

Ethics and dissemination: The study was approved by ethics committees at each centre and informed consent will be obtained for all patients. The trial is being performed under the auspices of an independent data and safety monitoring committee and is included in a broad dissemination strategy regarding revival of old antibiotics.

Trial registration number: NCT01732250 and 2012-004819-31; Pre-results.

Keywords: carbapenem-resistant Gram negative bacteria; colistin; combination therapy; meropenem.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

References

    1. Zhang L, Dhillon P, Yan H et al. . Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:3317–21. 10.1128/AAC.44.12.3317-3321.2000
    1. Hughes B, Madan BR, Parratt JR. Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol 1981;74:701–7.
    1. Sampson TR, Liu X, Schroeder MR et al. . Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother 2012;56:5642–9. 10.1128/AAC.00756-12
    1. Yahav D, Farbman L, Leibovici L et al. . Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012;18:18–29. 10.1111/j.1469-0691.2011.03734.x
    1. Paul M, Bishara J, Levcovich A et al. . Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65:1019–27. 10.1093/jac/dkq069
    1. Falagas ME, Rizos M, Bliziotis IA et al. . Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1 10.1186/1471-2334-5-1
    1. Falagas ME, Kasiakou SK, Kofteridis DP et al. . Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006;25:596–9. 10.1007/s10096-006-0191-2
    1. Pintado V, San Miguel LG, Grill F et al. . Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185–90. 10.1016/j.jinf.2008.01.003
    1. Cheng CY, Sheng WH, Wang JT et al. . Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297–300. 10.1016/j.ijantimicag.2009.11.016
    1. Falagas ME, Fragoulis KN, Kasiakou SK et al. . Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504–7. 10.1016/j.ijantimicag.2005.09.004
    1. Hartzell JD, Neff R, Ake J et al. . Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724–8. 10.1086/599225
    1. Deryke CA, Crawford AJ, Uddin N et al. . Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503–5. 10.1128/AAC.01707-09
    1. Kim J, Lee KH, Yoo S et al. . Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009;34:434–8. 10.1016/j.ijantimicag.2009.06.028
    1. Ko H, Jeon M, Choo E et al. . Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011;117:c284–8. 10.1159/000320746
    1. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011;62:187–90. 10.1016/j.jinf.2010.11.013
    1. Koch-Weser J, Sidel VW, Federman EB et al. . Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857–68.
    1. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27 10.1186/cc3995
    1. Qureshi ZA, Paterson DL, Potoski BA et al. . Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56:2108–13. 10.1128/AAC.06268-11
    1. Tumbarello M, Viale P, Viscoli C et al. . Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943–50. 10.1093/cid/cis588
    1. Batirel A, Balkan II, Karabay O et al. . Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311–22. 10.1007/s10096-014-2070-6
    1. Daikos GL, Tsaousi S, Tzouvelekis LS et al. . Carbapenemase- producing Klebsiella pneumoniae bloodstream infections: lowering mortality by anti-biotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322–8. 10.1128/AAC.02166-13
    1. Tumbarello M, Trecarichi EM, De Rosa FG et al. . Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70:2133–43. 10.1093/jac/dkv086
    1. Rigatto MH, Vieira FJ, Antochevis LC et al. . Polymyxin B in combination with in vitro non-susceptible antimicrobials versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2015;59:6575–80.
    1. Paul M, Carmeli Y, Durante-Mangoni E et al. . Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69:2305–9. 10.1093/jac/dku168
    1. Zusman A, Avni T, Leibovici L et al. . Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013;57:5104–11. 10.1128/AAC.01230-13
    1. Marcus R, Paul M, Elphick H et al. . Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 2011;37:491–503. 10.1016/j.ijantimicag.2010.11.029
    1. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111 10.1136/bmj.326.7399.1111
    1. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. . Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328:668 10.1136/bmj.38028.520995.63
    1. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32. 10.1016/j.ajic.2008.03.002
    1. Centers for Disease Control and Prevention (CDC). Improving surveillance for ventilator-associated events in adults 2012. (accessed 22 Jul 2015).
    1. Garonzik SM, Li J, Thamlikitkul V et al. . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284–94. 10.1128/AAC.01733-10
    1. Plachouras D, Karvanen M, Friberg LE et al. . Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430–6. 10.1128/AAC.01361-08
    1. European Medicines Agency completes review of polymyxin-based medicines. (accessed 25 Aug 2015).
    1. Couet W, Grégoire N, Marchand S et al. . Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012;18:30–9. 10.1111/j.1469-0691.2011.03667.x
    1. Mohamed AF, Karaiskos I, Plachouras D et al. . Application of a loading dose of colistin methanesulphonate in critically ill patients: population pharmacokinetics, protein binding and prediction of bacterial kill. Antimicrob Agents Chemother 2012;56:4241–9. 10.1128/AAC.06426-11
    1. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008;47(Suppl 1):S32–40. 10.1086/590064
    1. Spellberg B, Talbot G, Infectious Diseases Society of America (IDSA), American College of Chest Physicians (ACCP), American Thoracic Society (ATS) . Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010;51(Suppl 1):S150–70. 10.1086/653065
    1. Powers JH. Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis 2010;51(Suppl 1):S18–28. 10.1086/653036
    1. Bellomo R, Ronco C, Kellum JA et al. . Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204–12. 10.1186/cc2872
    1. Kristofferson AN, Friberg LE, Nyberg J. Inter occasion variability in individual optimal design. J Pharmacokinet Pharmacodyn 2015;42:735–50. 10.1007/s10928-015-9449-6
    1. Falagas ME, Tansarli GS, Karageorgopoulos DE et al. . Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerging Infect Dis 2014;20:1170–5. 10.3201/eid2007.121004
    1. Hussein K, Raz-Pasteur A, Finkelstein R et al. . Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumonia. J Hosp Infect 2013;83:307–13. 10.1016/j.jhin.2012.10.012
    1. Balkan II, Aygün G, Aydın S et al. . Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 2014;26:51–6. 10.1016/j.ijid.2014.05.012
    1. Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health 2011;8:15–20. 10.3390/ijerph8010015
    1. Quan H, Li B, Couris CM et al. . Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–82. 10.1093/aje/kwq433
    1. Falagas ME, Pitsouni EI, Bliziotis IA. Trends in the methodological quality of published randomized controlled trials on antibacterial agents. Br J Clin Pharmacol 2008;65:942–54. 10.1111/j.1365-2125.2008.03108.x
    1. Zimmermann JB, Horscht JJ, Weigand MA et al. . Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline. Int J Antimicrob Agents 2013;42:436–42. 10.1016/j.ijantimicag.2013.07.016
    1. Theuretzbacher U, Van Bambeke F, Cantón R et al. . Reviving old antibiotics. J Antimicrob Chemother 2015;70:2177–81. 10.1093/jac/dkv157
    1. Theuretzbacher U, Paul M. Revival of old antibiotics: structuring the re-development process to optimize usage. Clin Microbiol Infect 2015;21:878–80. 10.1016/j.cmi.2015.06.019
    1. Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens in special populations. Clin Microbiol Infect 2015; 21:886–93. 10.1016/j.cmi.2015.05.002
    1. Laterre PF, François B. Strengths and limitations of industry vs. academic randomised controlled trials. Clin Microbiol Infect 2015;21:906–9. 10.1016/j.cmi.2015.07.004
    1. Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 2015;21:899–905. 10.1016/j.cmi.2015.05.022
    1. Andersson DI. Improving predictions of the risk of resistance development against new and old antibiotics. Clin Microbiol Infect 2015;21:894–8. 10.1016/j.cmi.2015.05.012
    1. Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. Clin Microbiol Infect 2015;21:881–5. 10.1016/j.cmi.2015.06.007
    1. Nation RL, Li J, Cars O et al. . Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015;15:225–34. 10.1016/S1473-3099(14)70850-3
    1. Grégoire N, Mimoz O, Mégarbane B et al. . New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 2014;58:7324–30. 10.1128/AAC.03508-14
    1. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4. 10.1001/jama.2013.281053

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel